For HNSCC, we now have evidence from the KEYNOTE-048 trial to support the use of pembrolizumab in combination with platinum-based therapy, and pembrolizumab alone for PD-L1 expressing tumors.6 While both approaches are preferred over chemotherapy, pembrolizumab plus chemotherapy might be preferred for patients with significant symptom burden and those with a need for objective response. Here, CD274 is linked to head and neck squamous cell carcinoma.